Woodline Partners’s Viridian Therapeutics VRDN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.7M	Sell	700,929 -415,000	-37%	-$12.3M	0.05%	437
2025 Q4	$34.7M	Buy	1,115,929 +300,444	+37%	+$8.24M	0.13%	196
2025 Q3	$17.6M	Hold	815,485	–	–	0.08%	310
2025 Q2	$11.4M	Buy	815,485 +1,838	+0.2%	+$24.9K	0.06%	399
2025 Q1	$11M	Hold	813,647	–	–	0.07%	345
2024 Q4	$15.6M	Sell	813,647 -5,348	-0.7%	-$116K	0.11%	256
2024 Q3	$18.6M	Buy	818,995 +418,080	+104%	+$6.84M	0.16%	203
2024 Q2	$5.22M	Sell	400,915 -38,007	-9%	-$526K	0.05%	333
2024 Q1	$7.69M	Buy	+438,922	New	+$8.51M	0.07%	307
2023 Q3	–	Sell	-168,060	Closed	-$4M	–	753
2023 Q2	$4M	Buy	168,060 +48,611	+41%	+$1.25M	0.05%	329
2023 Q1	$3.04M	Sell	119,449 -204,690	-63%	-$6.56M	0.04%	369
2022 Q4	$9.47M	Buy	324,139 +28,265	+10%	+$651K	0.13%	221
2022 Q3	$6.07M	Sell	295,874 -256,497	-46%	-$4.61M	0.09%	265
2022 Q2	$6.39M	Buy	552,371 +331,114	+150%	+$4.45M	0.1%	225
2022 Q1	$4.09M	Sell	221,257 -36,413	-14%	-$700K	0.07%	263
2021 Q4	$5.09M	Buy	+257,670	New	+$4.8M	0.07%	278